Literature DB >> 9786480

In-vitro activities of amphotericin B, itraconazole and voriconazole against 150 clinical and environmental Aspergillus fumigatus isolates.

P E Verweij1, M Mensink, A J Rijs, J P Donnelly, J F Meis, D W Denning.   

Abstract

The in-vitro activity of amphotericin B, itraconazole and voriconazole against 130 clinical and 20 environmental Aspergillus fumigatus isolates was tested with an agar dilution method using RPMI 1640 medium. Itraconazole-susceptible (AF71) and -resistant (AF90) isolates were included in each test and all isolates were tested in duplicate. Geometric mean MIC values (ranges) at 48 h and 72 h were, respectively, amphotericin B, 0.91 (0.25-2) and 1.50 (1-4) mg/L; itraconazole, 0.25 (0.06-1) and 0.48 (0.125-8) mg/L; and voriconazole, 0.56 (0.25-8) and 0.78 (0.25-8) mg/L. The reproducibility of the results was high for all drugs. In-vitro resistance of A. fumigatus to the tested antifungal agents was uncommon and the MICs of itraconazole were half those of voriconazole (P < 0.01).

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9786480     DOI: 10.1093/jac/42.3.389

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  14 in total

1.  Identification of novel genes conferring altered azole susceptibility in Aspergillus fumigatus.

Authors:  Paul Bowyer; Juan Mosquera; Michael Anderson; Mike Birch; Michael Bromley; David W Denning
Journal:  FEMS Microbiol Lett       Date:  2012-05-21       Impact factor: 2.742

2.  Antifungal susceptibility and pathogenic potential of environmental isolated filamentous fungi compared with colonizing agents in immunocompromised patients.

Authors:  A B A Teixeira; M Silva; L Lyra; E A Luz; J Uno; H Takada; M Miyaji; K Nishimura; A Z Schreiber
Journal:  Mycopathologia       Date:  2005-09       Impact factor: 2.574

3.  Antifungal susceptibility of 596 Aspergillus fumigatus strains isolated from outdoor air, hospital air, and clinical samples: analysis by site of isolation.

Authors:  J Guinea; T Peláez; L Alcalá; M J Ruiz-Serrano; E Bouza
Journal:  Antimicrob Agents Chemother       Date:  2005-08       Impact factor: 5.191

4.  Efficacy of voriconazole in a guinea pig model of disseminated invasive aspergillosis.

Authors:  W R Kirkpatrick; R K McAtee; A W Fothergill; M G Rinaldi; T F Patterson
Journal:  Antimicrob Agents Chemother       Date:  2000-10       Impact factor: 5.191

5.  Combined activity in vitro of caspofungin, amphotericin B, and azole agents against itraconazole-resistant clinical isolates of Aspergillus fumigatus.

Authors:  Manuel Cuenca-Estrella; Alicia Gomez-Lopez; Guillermo Garcia-Effron; Laura Alcazar-Fuoli; Emilia Mellado; Maria J Buitrago; Juan L Rodriguez-Tudela
Journal:  Antimicrob Agents Chemother       Date:  2005-03       Impact factor: 5.191

Review 6.  Aspergillus fumigatus and aspergillosis: From basics to clinics.

Authors:  A Arastehfar; A Carvalho; J Houbraken; L Lombardi; R Garcia-Rubio; J D Jenks; O Rivero-Menendez; R Aljohani; I D Jacobsen; J Berman; N Osherov; M T Hedayati; M Ilkit; D James-Armstrong; T Gabaldón; J Meletiadis; M Kostrzewa; W Pan; C Lass-Flörl; D S Perlin; M Hoenigl
Journal:  Stud Mycol       Date:  2021-05-10       Impact factor: 16.097

7.  Azole cross-resistance in Aspergillus fumigatus.

Authors:  J Mosquera; D W Denning
Journal:  Antimicrob Agents Chemother       Date:  2002-02       Impact factor: 5.191

Review 8.  Pharmacology of itraconazole.

Authors:  K De Beule; J Van Gestel
Journal:  Drugs       Date:  2001       Impact factor: 9.546

9.  In vitro survey of triazole cross-resistance among more than 700 clinical isolates of Aspergillus species.

Authors:  M A Pfaller; S A Messer; L Boyken; C Rice; S Tendolkar; R J Hollis; D J Diekema
Journal:  J Clin Microbiol       Date:  2008-06-18       Impact factor: 5.948

10.  Comparison of Etest with modified broth microdilution method for testing susceptibility of Aspergillus spp. to voriconazole.

Authors:  M C Serrano; D Morilla; A Valverde; M Chávez; A Espinel-Ingroff; R Claro; M Ramírez; E Martín Mazuelos
Journal:  J Clin Microbiol       Date:  2003-11       Impact factor: 5.948

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.